Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Change in Receivables (2016 - 2020)

Plus Therapeutics (PSTV) has disclosed Change in Receivables for 11 consecutive years, with -$951000.0 as the latest value for Q3 2020.

  • Quarterly Change in Receivables fell 119.72% to -$951000.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$951000.0 through Jun 2021, down 199.37% year-over-year, with the annual reading at -$1.2 million for FY2020, 197.17% down from the prior year.
  • Change in Receivables for Q3 2020 was -$951000.0 at Plus Therapeutics, down from -$27000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $4.8 million in Q3 2019, with the low at -$3.6 million in Q4 2019.
  • Average Change in Receivables over 5 years is -$39105.3, with a median of -$138000.0 recorded in 2017.
  • Peak annual rise in Change in Receivables hit 11383.33% in 2019, while the deepest fall reached 2451.05% in 2019.
  • Over 5 years, Change in Receivables stood at $270000.0 in 2016, then crashed by 151.11% to -$138000.0 in 2017, then fell by 3.62% to -$143000.0 in 2018, then crashed by 2451.05% to -$3.6 million in 2019, then surged by 73.93% to -$951000.0 in 2020.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$951000.0, -$27000.0, and -$191000.0 for Q3 2020, Q2 2020, and Q1 2020 respectively.